Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...

Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine, a form of the drug ketamine, an anaesthetic commonly used illegally for recreational purposes.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

S-ketamine, also called esketamine (Spravato), is a nasal spray with FDA approval for treatment-resistant depression and major depressive disorder with suicidal ideation. Esketamine (Spravato ...